Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AnaptysBio, Inc. (ANAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on immunology therapeutics, AnaptysBio uses these filings to report material events related to its clinical programs, collaborations, capital allocation decisions and strategic plans.
Recent Form 8-K filings describe several categories of information. Some filings report results of operations and financial condition, where AnaptysBio furnishes press releases detailing quarterly financial results and business updates. Others fall under Regulation FD disclosure, such as filings that provide updated corporate investor presentations or slide decks used in conference calls discussing programs like ANB033 or the company’s broader pipeline.
Additional 8-Ks highlight other events, including board authorization of amendments to the company’s stock repurchase plan and the board’s approval of plans to explore separating AnaptysBio’s business into two independent, publicly traded companies by the end of 2026. Filings also cover the company’s Verified Complaint in Delaware Chancery Court against Tesaro and GSK concerning the Collaboration and Exclusive License Agreement for Jemperli, as well as references to Tesaro and GSK’s complaint against AnaptysBio.
For investors analyzing ANAB, these filings help clarify how AnaptysBio reports litigation developments, collaboration terms, royalty monetization arrangements, and major strategic decisions. On Stock Titan, SEC documents are paired with AI-powered summaries that explain the main points of each filing in plain language, highlight notable items such as litigation updates or changes to repurchase plans, and make it easier to scan multiple 8-Ks and other forms without reading every line of legal text.
ANAPTYSBIO, INC director Susannah Gray filed an initial Form 3 reporting her status as a director of the company. The filing does not list any reportable transactions or equity holdings, indicating this is a baseline disclosure of insider status rather than a trading event.
ANAPTYSBIO director John P. Schmid sold 20,645 shares of Common Stock in open-market transactions. All sales occurred on March 30, 2026 at weighted average prices ranging from $55.7087 to $57.3989 per share, within overall trade ranges of $55.20 to $57.92.
After these sales, Schmid directly holds 31,622 shares of ANAPTYSBIO Common Stock, according to the filing.
ANAPTYSBIO, INC President and CEO Daniel Faga received 34,300 performance-based restricted stock units (PSUs) after the compensation committee certified that specific performance goals were achieved on March 25, 2026. Each PSU represents a right to receive one share of common stock.
On March 27, 2026, Faga sold an aggregate of 17,679 shares of common stock in multiple open-market transactions at weighted-average prices ranging from the mid‑$50s to mid‑$60s per share. According to the disclosure, these sales were solely to cover tax withholding obligations from the PSU vesting and were not discretionary trades.
After these grant and tax-related sales, Faga holds 495,965 shares of AnaptysBio common stock directly, indicating that the transactions reflect routine compensation vesting and associated tax settlement rather than a change in his core equity position.
AnaptysBio is executing a major restructuring built around spinning off First Tracks Biotherapeutics and returning capital to shareholders. The board approved a pro rata spin-off of First Tracks, with holders of AnaptysBio stock receiving one First Tracks share for each AnaptysBio share held on April 6, 2026, with distribution expected before U.S. market open on April 20, 2026 and First Tracks trading on Nasdaq under “TRAX.”
To fund the new company, First Tracks and EcoR1 Capital agreed to a $145 million private placement at $13.81 per share, including 5,791,478 primary shares generating about $80 million in gross proceeds for First Tracks and 4,705,576 secondary shares sold by EcoR1. AnaptysBio also terminated its prior at‑the‑market equity program and authorized a stock repurchase plan of up to $100 million. Governance changes include appointing Susannah Gray as a director and putting executive transition and separation agreements in place for Dennis Mulroy and Eric Loumeau tied to the spin-off.
AnaptysBio Inc filed an Amendment No. 1 to Schedule 13G/A reporting that The Vanguard Group holds 0 shares of Common Stock, representing 0% of the class after an internal realignment. The filing states Vanguard subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.
AnaptysBio, Inc. is a clinical-stage biotechnology company developing antibody therapies for autoimmune and inflammatory diseases. Its wholly owned pipeline includes rosnilimab, which delivered statistically significant Phase 2b results in moderate-to-severe rheumatoid arthritis, plus ANB033 in Phase 1b trials for celiac disease and eosinophilic esophagitis, and ANB101 in a Phase 1 trial targeting BDCA2 on plasmacytoid dendritic cells.
The company also earns milestones and royalties from partnered antibodies. GSK’s PD‑1 drug Jemperli generated $1.1 billion in 2025 sales, up from $598.0 million in 2024. Vanda holds global rights to imsidolimab for generalized pustular psoriasis, with a BLA accepted by the FDA and a target action date of December 12, 2026.
In September 2025, AnaptysBio’s board approved plans to pursue a separation into two independent public companies, one focused on managing Jemperli and imsidolimab financial collaborations and one focused on advancing its clinical immunology pipeline. The separation is expected in the second quarter of 2026, subject to board approval and SEC registration effectiveness.
AnaptysBio plans to separate its biopharma operations into a new public company, First Tracks Biotherapeutics, in Q2 2026, while the existing company will focus on managing royalty streams from Jemperli with GSK and imsidolimab with Vanda. A Form 10 for the spin-off has been filed, and leadership and board line-ups for First Tracks are outlined.
For Q4 2025, collaboration revenue rose to $108.2 million and AnaptysBio generated net income of $49.6 million, versus a loss a year earlier, driven largely by Jemperli milestones and higher royalties. For 2025, collaboration revenue reached $234.6 million, with a narrowed net loss of $13.2 million. Cash, cash equivalents and investments were $311.6 million as of December 31, 2025, after repurchasing 3.44 million shares under a $175 million program.
LOUMEAU ERIC J reported multiple insider transaction types in a Form 4 filing for ANAB. The filing lists transactions totaling 30,000 shares at a weighted average price of $41.85 per share. Following the reported transactions, holdings were 35,000 shares.
AnaptysBio insider Eric J. Loumeau has filed a Form 144 to sell 10,000 shares of the company’s common stock. The shares are to be sold through Morgan Stanley Smith Barney on NASDAQ, with an indicated aggregate market value of 540000.00, and are part of a class with 27,688,470 shares outstanding.
The 10,000 shares were acquired on 02/11/2026 via a stock option exercise from the issuer, paid in cash on the same date. The filing also lists multiple prior open-market sales of AnaptysBio common stock by Loumeau over the past three months, including 10,000-share blocks sold on 12/17/2025 and 12/22/2025 for gross proceeds of 460000.00 and 510000.00, respectively.